September 24, 2008
Kuros and Aeris Sign Licensing Agreement
Switzerland-based Kuros Biosurgery has granted US-based Aeris Therapeutics an exclusive license in the field of lung volume reduction to certain patent rights Kuros exclusively licensed from the American Red Cross that cover the delivery of certain drugs in a fibrin sealant.
In return for the license, Kuros will receive upfronts, milestones and royalties on the sale of Aeris's lead product, the AeriSeal biologic lung volume reduction (BLVR) system, a novel investigational emphysema treatment. Aeris is currently preparing for the initiation of Phase III clinical trials for the AeriSeal BLVR system.
David Dove, CEO of Aeris, said: "The licensing of this IP from Kuros is an important step in the continued development of our unique BLVR system. We believe that BLVR has the potential to offer patients suffering from emphysema a treatment option that can alleviate their symptoms of shortness of breath and improve quality of life."